MedTrace Logo

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)

NCT04298060 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2020-07-09

No results posted yet for this study

Summary

This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.

Conditions

  • Influenza Infection
  • SAD-RV Infection and COVID-19

Interventions

DRUG

DAS181

SD (4.5mg/day), HD (9mg/day)

DRUG

Placebo

Placebo 0mg/day

Sponsors & Collaborators

  • Ansun Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Jennifer Ho, MD, PhD · Ansun Biopharma, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2021-03-31
Completion
2022-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04298060 on ClinicalTrials.gov